Faculty profile

Nigil Haroon

ResearcherImmunology and RheumatologyUniversity of Toronto

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Toronto directory, so their courses and email address may be missing. Find their university profile.

Nigil Haroon

Researcher

Immunology and Rheumatology

Health Sciences

University of Toronto

Toronto, Ontario, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
37 publications in the last five years, latest in 2026.
Senior (last) author on 11 recent papers, a sign of leading a research group.
Principal investigator on 8 research grants (8 CIHR), most recently in 2025.
Supervised 2 trainees who won CIHR awards, most recently in 2025.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

112

Publications

766

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Arthritis Inflammation Spondyloarthritis Autophagy Hla-B27 Deubiquitinase Trabid Antigen Presentation

Latest papers

Reduction of CXCR3+CCR6+ CD4+ T Cells and IL-17+ RORγt+ CD4+ T Cells During Secukinumab Treatment Identifies Patients With Axial Spondyloarthritis Responsive to Subsequent Biologic Therapy.
ACR open rheumatology · 2026
T cells, the Next Big Target in Axial Spondyloarthritis?
Arthritis & rheumatology (Hoboken, N.J.) · 2026 · senior author
FOXO3a Polymorphisms Are Not Associated With Axial Spondyloarthritis or Psoriatic Arthritis Susceptibility in a Canadian Cohort, With Ancestry-Specific Findings.
International journal of rheumatic diseases · 2026

All 112 publications

Latest funding

TRABID and anti-inflammatory checkpoint factors in SpA
CIHR · 2025 · Nominated PI
$302,174
Sec16A-Mediated Autophagy and HLA-B27 Trafficking: Mechanistic Insights Into Antigen Presentation in Axial Spondyloarthritis
CIHR · 2025 · Nominated PI
$344,250
The Role of the Immunometabolism in Spondyloarthritis Drug Response Outcomes
CIHR · 2025 · Supervisor
$120,000

All 13 grants and awards

112 publications.

Reduction of CXCR3+CCR6+ CD4+ T Cells and IL-17+ RORγt+ CD4+ T Cells During Secukinumab Treatment Identifies Patients With Axial Spondyloarthritis Responsive to Subsequent Biologic Therapy.

Pacheco A, Remalante-Rayco P, Haroon N, Poddubnyy D, Inman RD

ACR open rheumatology2026

DOI: 10.1002/acr2.90093 PMID: 42666100

T cells, the Next Big Target in Axial Spondyloarthritis?

Aparnathi MK, Haroon N

Arthritis & rheumatology (Hoboken, N.J.)2026Senior author

DOI: 10.1002/art.70221 PMID: 42112876

FOXO3a Polymorphisms Are Not Associated With Axial Spondyloarthritis or Psoriatic Arthritis Susceptibility in a Canadian Cohort, With Ancestry-Specific Findings.

Pacheco A, Rahman P, Chandran V, Haroon N, Inman RD

International journal of rheumatic diseases2026

DOI: 10.1111/1756-185x.70745 PMID: 42325075

Certolizumab Pegol Reduced Anterior Uveitis Flares Compared With Standard Non-Biologic Treatment: Results From an Overlap Weighting Analysis in High-Risk Patients With Axial Spondyloarthritis.

Haroon N, Baskurt Z, Chim T, Inman RD, Kumke T, Tham R, Kim M, van der Horst-Bruinsma I, Gensler LS

International journal of rheumatic diseases2026First author

DOI: 10.1111/1756-185x.70621 PMID: 41919656

Determinants of Difficult-to-Manage and Treatment-Refractory Axial Spondyloarthritis: A Cross-Sectional Analysis Within a Longitudinal Cohort.

Remalante-Rayco P, Passalent L, Chim T, Vijayan H, Alnasser M, Baskurt Z, Inman RD, Haroon N, Poddubnyy D

Arthritis & rheumatology (Hoboken, N.J.)2026

DOI: 10.1002/art.70202 PMID: 42045797

Segmental spinal damage predicts mobility restriction and functional decline in radiographic axial spondyloarthritis: a longitudinal study.

Sari I, Lee S, Johnson SR, Inman RD, Haroon N

Rheumatology (Oxford, England)2026Senior author

DOI: 10.1093/rheumatology/keag131 PMID: 41834142

Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada Living Treatment Recommendations for the Management of Axial Spondyloarthritis: Update #1

Richard N, Pardo JP, Mirza R, Aydin SZ, Bessette L, Mosher D, Boyd T, Chan J, Eder L, Passalent L

Journal of Rheumatology2026

DOI: 10.3899/jrheum.2026-0227

Impact of disease manifestations on first biologic drug survival in axial spondyloarthritis: a real-life Canadian study.

Hurtubise R, Rohekar S, Haroon N, Baskurt Z, Chim T, Zummer M, Inman RD, Richard N, SpondyloArthritis Research Consortium of Canada (SPARCC)

Rheumatology advances in practice2025

DOI: 10.1093/rap/rkaf004 PMID: 39886539

Inflammatory bowel disease does not confer higher disease activity or greater radiographic progression in axial spondyloarthritis.

Remalante-Rayco P, Daghistani Y, Chim T, Baskurt Z, Keshavarzi S, Passalent L, Poddubnyy D, Inman RD, Haroon N

Rheumatology (Oxford, England)2025Senior author

DOI: 10.1093/rheumatology/keaf420 PMID: 40824393

Impact of clinical subtype and sex on first-line biologic therapy discontinuation in axial spondyloarthritis.

Remalante-Rayco P, Baja ES, Baskurt Z, Chim T, Panelo CIA, Osio-Salido E, Inman RD, Dans LF, Haroon N

Annals of the rheumatic diseases2025Senior author

DOI: 10.1016/j.ard.2025.01.007 PMID: 39919972

Something wrong or missing on this profile? Suggest a correction

Nigil Haroon

Research

Latest papers

Latest funding

Reduction of CXCR3+CCR6+ CD4+ T Cells and IL-17+ ROR&#x3b3;t+ CD4+ T Cells During Secukinumab Treatment Identifies Patients With Axial Spondyloarthritis Responsive to Subsequent Biologic Therapy.

T cells, the Next Big Target in Axial Spondyloarthritis?

FOXO3a Polymorphisms Are Not Associated With Axial Spondyloarthritis or Psoriatic Arthritis Susceptibility in a Canadian Cohort, With Ancestry-Specific Findings.

Certolizumab Pegol Reduced Anterior Uveitis Flares Compared With Standard Non-Biologic Treatment: Results From an Overlap Weighting Analysis in High-Risk Patients With Axial Spondyloarthritis.

Determinants of Difficult-to-Manage and Treatment-Refractory Axial Spondyloarthritis: A Cross-Sectional Analysis Within a Longitudinal Cohort.

Segmental spinal damage predicts mobility restriction and functional decline in radiographic axial spondyloarthritis: a longitudinal study.

Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada Living Treatment Recommendations for the Management of Axial Spondyloarthritis: Update #1

Impact of disease manifestations on first biologic drug survival in axial spondyloarthritis: a real-life Canadian study.

Inflammatory bowel disease does not confer higher disease activity or greater radiographic progression in axial spondyloarthritis.

Impact of clinical subtype and sex on first-line biologic therapy discontinuation in axial spondyloarthritis.

Frequent collaborators

Vinod Chandran

Proton Rahman

Dianne Mosher

Proton Rahman

Richard Cook

Jessica Widdifield

Lihi Eder

Robert Inman

Zahi Touma

Mohit Kapoor

Igor Jurisica

Sareh Keshavarzi

Carter Thorne

Arielle Mendel

Arielle Mendel

Rahim Moineddin

Sasha Bernatsky

Sasha Bernatsky

Simone Vigod

Reza Donald Mirza

Yasir Mohamud

Thomas Pulinilkunnil

Ina Dobrinski

Rajiv Gandhi

Vincent Piguet

Steve Jean

Khosrow Adeli

Sophie Roux

Honglin Luo

Sandra Turcotte

Claire Bombardier

Gary Sweeney

Elie Akl

Isabella Caniggia

J Michael Paterson

Michael Sacher

Martin Post

Sabah Hussain

Anne-Claude Gingras

Caigan Du

Reduction of CXCR3+CCR6+ CD4+ T Cells and IL-17+ RORγt+ CD4+ T Cells During Secukinumab Treatment Identifies Patients With Axial Spondyloarthritis Responsive to Subsequent Biologic Therapy.